

# Supplementary Material

## **Metallothionein 3 Potentiates Pulmonary Artery Smooth Muscle Cell Proliferation by Promoting Zinc-MTF1-ATG5 Axis-mediated Autophagosome Formation**

Tianxin Xiong<sup>1\*</sup>, Yi Li<sup>1\*</sup>, Molin Yang<sup>1</sup>, Bo Huo<sup>1</sup>, Xian Guo<sup>1</sup>, Liyuan Liu<sup>2</sup>, Yanxin Huang<sup>2</sup>, Xuehai Zhu<sup>1,3</sup>, Qinghua Hu<sup>4,5</sup>, Xiang Wei<sup>1,3#</sup>, Ding-Sheng Jiang<sup>1,3#</sup>, Xin Yi<sup>2#</sup>

<sup>1</sup>Division of Cardiovascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; <sup>2</sup>Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China; <sup>3</sup>Key Laboratory of Organ Transplantation, Ministry of Education; NHC Key Laboratory of Organ Transplantation; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, Hubei, China; <sup>4</sup>Key Laboratory of Pulmonary Diseases of Ministry of Health of China, Wuhan, China; <sup>5</sup>Department of Pathophysiology, School of Basic Medicine, Huazhong University of Science and Technology, Wuhan, China.

**\*Tianxin Xiong and Yi Li contribute equally to this work**

**Correspondence to**

**Xin Yi, MD**

Department of Cardiology, Renmin Hospital of Wuhan University,

Jiefang Road 238, Wuhan, China.

E-mail: [yixin2022@whu.edu.cn](mailto:yixin2022@whu.edu.cn)

Or

**Ding-Sheng Jiang, MD**

Division of Cardiovascular Surgery

Tongji Hospital, Tongji Medical College

Huazhong University of Science and Technology

1095 Jiefang Ave., Wuhan 430030, China

Tel/Fax: 86-27-6937-8454; E-mail: [jds@hust.edu.cn](mailto:jds@hust.edu.cn)

Or

**Xiang Wei, MD**

Division of Cardiovascular Surgery

Tongji Hospital, Tongji Medical College


Huazhong University of Science and Technology

1095 Jiefang Ave., Wuhan 430030, China

Tel/Fax: 86-27-6937-8454; E-mail: [xiangwei@tjh.tjmu.edu.cn](mailto:xiangwei@tjh.tjmu.edu.cn)


## Supplemental Figures

### Supplemental Figure S1




**Supplemental Figure S1. MT3 expression level is not altered in the endothelium of pulmonary arteries from PH patients and chronic hypoxia-induced model rat. A,** Representative images showing immunofluorescence staining against vWF (green) and MT3 (red) in the pulmonary arteries (PAs) from normal and PH patients (scale bar, 20 μm). **B,** Mean fluorescence intensity (MFI) of MT3 in the endothelium (quantified as the intensity of red fluorescence in the vWF-positive area) of PAs in normal controls and PH patients (n=3). **C,** Representative images showing immunofluorescence staining against vWF and MT3 in PAs from normoxia and 4-week hypoxia-treated rats (scale bar, 20 μm). **D,** Mean fluorescence intensity (MFI) of MT3 in the endothelium of PAs from normoxia- and hypoxia-treated rats (n=6). n.s indicates no significant difference.

## Supplemental Figure S2




**Supplemental Figure S2. MT3 expression level is increased in the tunica media of pulmonary arteries from MCT-induced and SuHx-induced model rats. A,** Representative images showing immunofluorescence staining against  $\alpha$ -SMA (green) and MT3 (red) from pulmonary arteries (PAs) in control and monocrotaline (MCT)-treated rats (scale bar, 20  $\mu$ m). **B,** Quantification of tunica medial wall thickness [(outer diameter–inner diameter)/outer diameter] of the PAs in the control and MCT-treated groups,  $\alpha$ -SMA marks the tunica media of the pulmonary arteries (n=6). **C,** Mean fluorescence intensity (MFI) of MT3 in the tunica media (quantified as the intensity of red fluorescence in the  $\alpha$ -SMA-positive area) of PAs in control and MCT-treated groups (n=6). **D,** Representative images showing immunofluorescence staining against  $\alpha$ -SMA and MT3 from PAs in control and Sugden5416 combined with hypoxia (SuHx)-treated rats (scale bar, 20  $\mu$ m). **E and F,** Medial wall thickness and MT3 expression levels in the tunica media of PAs were quantified in control and SuHx-treated rats, and quantitative methods are consistent with **B** and **C** (n=6). \*\*P<0.01, \*\*\*P<0.001.

### Supplemental Figure S3



**Supplemental Figure S3. Neither overexpression nor knockdown of MT3 affects the cell death of HPASMCs. A and B,** Cell survival rate of HPASMCs knockdown (or not) or overexpression (or not) of MT3 subjected to 24 hours of normoxia or hypoxia treatment was assessed by LDH assay (n=6). n.s indicates no significant difference.

## Supplemental Figure S4



**Supplemental Figure S4. The expression level of MT3 does not affect the release of ROS.** **A** and **B**, Representative images and quantitative analysis of mean fluorescence intensity of ROS in HPASMCs of the MT3 knockdown (or not) groups subjected to 48 hours normoxia/hypoxia by flow cytometry (n=6). **C** and **D**, Representative images and quantitative analysis of mean fluorescence intensity of ROS in HPASMCs of the MT3 overexpression (or not) by flow cytometry (n=6). n.s indicates no significant difference, \*\*\*  $P < 0.001$ .